Sandhill Capital Partners LLC Sells 56,556 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Sandhill Capital Partners LLC decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 286,694 shares of the medical equipment provider’s stock after selling 56,556 shares during the period. Zimmer Biomet accounts for 2.9% of Sandhill Capital Partners LLC’s portfolio, making the stock its 16th largest position. Sandhill Capital Partners LLC’s holdings in Zimmer Biomet were worth $34,891,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. PFG Advisors lifted its stake in Zimmer Biomet by 4.6% in the fourth quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider’s stock valued at $231,000 after buying an additional 84 shares during the period. Quent Capital LLC raised its position in shares of Zimmer Biomet by 21.6% during the fourth quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after purchasing an additional 92 shares during the period. Pinnacle Associates Ltd. raised its position in shares of Zimmer Biomet by 5.0% during the third quarter. Pinnacle Associates Ltd. now owns 2,020 shares of the medical equipment provider’s stock worth $227,000 after purchasing an additional 97 shares during the period. Financial Advocates Investment Management raised its position in shares of Zimmer Biomet by 3.8% during the third quarter. Financial Advocates Investment Management now owns 2,625 shares of the medical equipment provider’s stock worth $295,000 after purchasing an additional 97 shares during the period. Finally, Stokes Family Office LLC raised its position in shares of Zimmer Biomet by 4.1% during the third quarter. Stokes Family Office LLC now owns 2,498 shares of the medical equipment provider’s stock worth $280,000 after purchasing an additional 99 shares during the period. Institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. JPMorgan Chase & Co. raised their price target on Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research report on Friday, February 9th. TheStreet raised Zimmer Biomet from a “c” rating to a “b-” rating in a research report on Thursday, February 8th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $130.00 price target on shares of Zimmer Biomet in a research report on Friday, February 23rd. StockNews.com lowered Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 19th. Finally, Barclays lifted their target price on Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research report on Monday, February 12th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $139.39.

Insider Transactions at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the transaction, the vice president now directly owns 44,145 shares in the company, valued at approximately $5,677,929.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.95% of the stock is currently owned by corporate insiders.

Zimmer Biomet Stock Down 1.2 %

ZBH stock traded down $1.42 during mid-day trading on Thursday, reaching $119.75. The company had a trading volume of 1,078,771 shares, compared to its average volume of 1,453,584. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.61 and a quick ratio of 0.78. Zimmer Biomet Holdings, Inc. has a 52 week low of $102.00 and a 52 week high of $149.25. The stock has a 50 day simple moving average of $126.18 and a two-hundred day simple moving average of $119.46. The company has a market capitalization of $24.60 billion, a price-to-earnings ratio of 24.47, a PEG ratio of 2.23 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping the consensus estimate of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. During the same period in the previous year, the company posted $1.88 EPS. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. As a group, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.80%. Zimmer Biomet’s dividend payout ratio is currently 19.63%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.